Novel mechanisms of myocardial ischemia, ischemia-reperfusion, and protection by myocardial conditioning

Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3

Jan Neckář, Anna Hsu, Md Abdul Hye Khan, Garrett J. Gross, Kasem Nithipatikom, Michaela Cyprová, Daniel Benák, Markéta Hlaváčková, Dita Sotáková-Kašparová, J R Falck, David Sedmera, František Kolář, John D. Imig

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epoxyeicosatr-ienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1β in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3% in control to 42.6 ± 1.9% and 46.0 ± 1.6%, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyei-cosa-5(Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1%). Similarly, the HIF-1β inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1β and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1β immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78% vs. 0.34 ± 0.08%). After 20 min and 2 h of reperfusion, HIF-1β immunoreactivity decreased to 2.40 ± 0.48% and 1.85 ± 0.43%, respectively, in the controls. EET-B blunted the decrease of HIF-1β immunoreactivity (7.80 ± 0.69% and 6.44 ± 1.37%, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1β and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1β levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor-1β-degrading enzyme prolyl hydroxylase domain protein 3.

Original languageEnglish (US)
Pages (from-to)H1148-H1158
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume315
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

Hypoxia-Inducible Factor 1
Reperfusion
Myocardial Ischemia
Down-Regulation
Ischemia
Myocardial Infarction
Prolyl Hydroxylases
Acids
Enzymes
Acriflavine
2-oxoglutarate 3-dioxygenase proline
Coronary Occlusion
Reperfusion Injury
Coronary Vessels

Keywords

  • Epoxyeicosatrienoic acid
  • Heart
  • Hypoxia-inducible factor-1β
  • Ischemia-reperfusion
  • Prolyl hydroxylase 3

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Novel mechanisms of myocardial ischemia, ischemia-reperfusion, and protection by myocardial conditioning : Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3. / Neckář, Jan; Hsu, Anna; Hye Khan, Md Abdul; Gross, Garrett J.; Nithipatikom, Kasem; Cyprová, Michaela; Benák, Daniel; Hlaváčková, Markéta; Sotáková-Kašparová, Dita; Falck, J R; Sedmera, David; Kolář, František; Imig, John D.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 315, No. 5, 01.10.2018, p. H1148-H1158.

Research output: Contribution to journalArticle

Neckář, Jan ; Hsu, Anna ; Hye Khan, Md Abdul ; Gross, Garrett J. ; Nithipatikom, Kasem ; Cyprová, Michaela ; Benák, Daniel ; Hlaváčková, Markéta ; Sotáková-Kašparová, Dita ; Falck, J R ; Sedmera, David ; Kolář, František ; Imig, John D. / Novel mechanisms of myocardial ischemia, ischemia-reperfusion, and protection by myocardial conditioning : Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3. In: American Journal of Physiology - Heart and Circulatory Physiology. 2018 ; Vol. 315, No. 5. pp. H1148-H1158.
@article{d594e00c6ee54cbbb2b361e7021abd88,
title = "Novel mechanisms of myocardial ischemia, ischemia-reperfusion, and protection by myocardial conditioning: Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3",
abstract = "Epoxyeicosatr-ienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1β in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3{\%} in control to 42.6 ± 1.9{\%} and 46.0 ± 1.6{\%}, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyei-cosa-5(Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1{\%}). Similarly, the HIF-1β inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1β and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1β immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78{\%} vs. 0.34 ± 0.08{\%}). After 20 min and 2 h of reperfusion, HIF-1β immunoreactivity decreased to 2.40 ± 0.48{\%} and 1.85 ± 0.43{\%}, respectively, in the controls. EET-B blunted the decrease of HIF-1β immunoreactivity (7.80 ± 0.69{\%} and 6.44 ± 1.37{\%}, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1β and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1β levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor-1β-degrading enzyme prolyl hydroxylase domain protein 3.",
keywords = "Epoxyeicosatrienoic acid, Heart, Hypoxia-inducible factor-1β, Ischemia-reperfusion, Prolyl hydroxylase 3",
author = "Jan Neck{\'a}ř and Anna Hsu and {Hye Khan}, {Md Abdul} and Gross, {Garrett J.} and Kasem Nithipatikom and Michaela Cyprov{\'a} and Daniel Ben{\'a}k and Mark{\'e}ta Hlav{\'a}čkov{\'a} and Dita Sot{\'a}kov{\'a}-Kašparov{\'a} and Falck, {J R} and David Sedmera and František Kol{\'a}ř and Imig, {John D.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1152/ajpheart.00726.2017",
language = "English (US)",
volume = "315",
pages = "H1148--H1158",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "5",

}

TY - JOUR

T1 - Novel mechanisms of myocardial ischemia, ischemia-reperfusion, and protection by myocardial conditioning

T2 - Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3

AU - Neckář, Jan

AU - Hsu, Anna

AU - Hye Khan, Md Abdul

AU - Gross, Garrett J.

AU - Nithipatikom, Kasem

AU - Cyprová, Michaela

AU - Benák, Daniel

AU - Hlaváčková, Markéta

AU - Sotáková-Kašparová, Dita

AU - Falck, J R

AU - Sedmera, David

AU - Kolář, František

AU - Imig, John D.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Epoxyeicosatr-ienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1β in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3% in control to 42.6 ± 1.9% and 46.0 ± 1.6%, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyei-cosa-5(Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1%). Similarly, the HIF-1β inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1β and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1β immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78% vs. 0.34 ± 0.08%). After 20 min and 2 h of reperfusion, HIF-1β immunoreactivity decreased to 2.40 ± 0.48% and 1.85 ± 0.43%, respectively, in the controls. EET-B blunted the decrease of HIF-1β immunoreactivity (7.80 ± 0.69% and 6.44 ± 1.37%, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1β and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1β levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor-1β-degrading enzyme prolyl hydroxylase domain protein 3.

AB - Epoxyeicosatr-ienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1β in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3% in control to 42.6 ± 1.9% and 46.0 ± 1.6%, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyei-cosa-5(Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1%). Similarly, the HIF-1β inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1β and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1β immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78% vs. 0.34 ± 0.08%). After 20 min and 2 h of reperfusion, HIF-1β immunoreactivity decreased to 2.40 ± 0.48% and 1.85 ± 0.43%, respectively, in the controls. EET-B blunted the decrease of HIF-1β immunoreactivity (7.80 ± 0.69% and 6.44 ± 1.37%, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1β and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1β levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor-1β-degrading enzyme prolyl hydroxylase domain protein 3.

KW - Epoxyeicosatrienoic acid

KW - Heart

KW - Hypoxia-inducible factor-1β

KW - Ischemia-reperfusion

KW - Prolyl hydroxylase 3

UR - http://www.scopus.com/inward/record.url?scp=85054889895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054889895&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00726.2017

DO - 10.1152/ajpheart.00726.2017

M3 - Article

VL - 315

SP - H1148-H1158

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 5

ER -